BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH PatientsGlobeNewsWire • 10/28/19
U.S. Government Exercises Option for Additonal Rapivab® for Strategic National StockpileGlobeNewsWire • 09/26/19
BioCryst Pharmaceuticals Inc. Represents Good Entry Opportunity At Current PricesSeeking Alpha • 09/09/19
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/06/19
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/19
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/19
BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug TrialBenzinga • 05/21/19
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19
Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock OptionsZacks Investment Research • 04/04/19